➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
AstraZeneca
McKinsey
Harvard Business School
Johnson and Johnson

Last Updated: August 15, 2020

DrugPatentWatch Database Preview

Doxazosin mesylate - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for doxazosin mesylate and what is the scope of freedom to operate?

Doxazosin mesylate is the generic ingredient in three branded drugs marketed by Upjohn, Accord Hlthcare, Actavis Elizabeth, Ani Pharms Inc, Apotex, Dava Pharms Inc, Genpharm, Heritage Pharma, Ivax Sub Teva Pharms, Mylan, Nesher Pharms, Pliva, Teva, Upsher Smith Labs, Watson Labs Inc, Yaopharma Co Ltd, and Zydus Pharms, and is included in nineteen NDAs. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for doxazosin mesylate. Twenty-eight suppliers are listed for this compound.

Drug Prices for doxazosin mesylate

See drug prices for doxazosin mesylate

Drug Sales Revenue Trends for doxazosin mesylate

See drug sales revenues for doxazosin mesylate

Recent Clinical Trials for doxazosin mesylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
PfizerN/A
National Heart, Lung, and Blood Institute (NHLBI)Phase 2
University of Minnesota - Clinical and Translational Science InstitutePhase 2

See all doxazosin mesylate clinical trials

Pharmacology for doxazosin mesylate
Medical Subject Heading (MeSH) Categories for doxazosin mesylate
Paragraph IV (Patent) Challenges for DOXAZOSIN MESYLATE
Tradename Dosage Ingredient NDA Submissiondate
CARDURA TABLET;ORAL doxazosin mesylate 019668

US Patents and Regulatory Information for doxazosin mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ivax Sub Teva Pharms DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075453-002 Oct 18, 2000 DISCN No No   Start Trial   Start Trial   Start Trial
Heritage Pharma DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 205210-002 Feb 13, 2018 AB RX No No   Start Trial   Start Trial   Start Trial
Nesher Pharms DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075609-002 Oct 18, 2000 DISCN No No   Start Trial   Start Trial   Start Trial
Zydus Pharms DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 208719-001 Jul 7, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Dava Pharms Inc DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 076161-002 Jun 10, 2004 AB RX No No   Start Trial   Start Trial   Start Trial
Zydus Pharms DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 208719-003 Jul 7, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for doxazosin mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Upjohn CARDURA XL doxazosin mesylate TABLET, EXTENDED RELEASE;ORAL 021269-002 Feb 22, 2005   Start Trial   Start Trial
Upjohn CARDURA doxazosin mesylate TABLET;ORAL 019668-002 Nov 2, 1990   Start Trial   Start Trial
Upjohn CARDURA doxazosin mesylate TABLET;ORAL 019668-001 Nov 2, 1990   Start Trial   Start Trial
Upjohn CARDURA doxazosin mesylate TABLET;ORAL 019668-003 Nov 2, 1990   Start Trial   Start Trial
Upjohn CARDURA doxazosin mesylate TABLET;ORAL 019668-004 Nov 2, 1990   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Colorcon
McKinsey
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.